Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Garp1on Dec 04, 2022 2:06pm
219 Views
Post# 35149623

RE:RE:How long must we wait

RE:RE:How long must we wait
Again, it’s not by throwing away money against the wind and hoping for a miracle that a company survives, but trough a clear-cut strategy that protect the business and shareholders wealth in order to survive and thrive in the future.

Paul laid out clearly that the trial up to now is a failure in terms of efficacy and safety. He laid out a fuzzy plan for the future without any underlying support or proof of a meaningful chance of success. He is willing to dish out substantial funds to continue in this approach at the expense of the company. He did not engage in a financial rationalization to cut costs to a bare minimum in regards to this trial and any underlying costs.

Thera like any other company is in the business of making money and even more money, it’s not in the business of trying to save failing products at the expense of its own survival.

It would seem that this CEO and the board have lost the main goal and objective of a company and are working under arcane or personal objectives.

Right now Thera should be searching for a mean to reinforce and increase the sales of their existing products, maximize costs reduction not related to sales, look for other ways to increase the company's wealth. Any attempt to pursue the present trial should not be undertaken until a postmortem analysis is done which would show a clear possibility of success if it is restarted.

I have watched this board speculate on the meaning of each word given by Paul and Thera against this trial and in the end, the fact is that what was told, only served the interest of keeping us busy while they were going nowhere and keeping everybody in the dark.
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse